Drug Profile


Alternative Names: Adecut; Alindapril; Cupressin; CV-3317; Delacard; Delaket; Delakete; Delapril hydrochloride; Indalapril; REV 6000A

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda
  • Developer Chiesi; Grunenthal; Paiboon Watana; Takeda; TORREX Pharma
  • Class Antihypertensives; Indans
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Heart failure; Hypertension

Most Recent Events

  • 23 Oct 2000 Launched for Hypertension in Brazil (PO)
  • 13 Oct 2000 Discontinued-II for Heart failure in Japan (PO)
  • 13 Oct 2000 Discontinued-III for Hypertension in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top